1 Overblown Biotech Selloff
Shares of prostate cancer drugmaker Medivation closed down 6% after reporting fourth-quarter earnings, despite handily beating expectations. Sales of its flagship product Xtandi racked up $57 million in its first full quarter. Its conference call was full of questions regarding the launch, as well as discussion over a controversial research report. Watch as health-care analyst David Williamson takes you through the day's events.
Resurgence, or dead cat bounce?
Shares of Medivation's competitor Dendreon have surged in recent months, with the stock gaining new life from the depths of late 2012. Has the company really solved its underlying problems, or are investors setting themselves up for more disappointment? Our new premium research report on Dendreon answers these questions, and many more, while also outlining just how Dendreon intends to regain its former glory. Claim your copy, and a year of free analyst updates, by clicking here now.
The article 1 Overblown Biotech Selloff originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Follow him on Twitter: @MotleyDavid.The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.